View Financial HealthAqua Bio Technology 배당 및 자사주 매입배당 기준 점검 0/6Aqua Bio Technology 현재 배당금을 지급하지 않습니다.핵심 정보0%배당 수익률-2.2%자사주 매입 수익률총 주주 수익률-2.2%미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향0%최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updatesNew Risk • May 13New major risk - Revenue sizeThe company makes less than US$1m in revenue. Total revenue: kr7.5m (US$822k) This is considered a major risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (633% average daily change). Earnings have declined by 62% per year over the past 5 years. Shareholders have been substantially diluted in the past year (over 6x increase in shares outstanding). Revenue is less than US$1m (kr7.5m revenue, or US$822k). Market cap is less than US$10m (€7.17m market cap, or US$8.40m).공시 • Mar 21Aqua Bio Technology ASA has completed a Follow-on Equity Offering in the amount of NOK 3.6824 million.Aqua Bio Technology ASA has completed a Follow-on Equity Offering in the amount of NOK 3.6824 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 388,240 Price\Range: NOK 5 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 348,240 Price\Range: NOK 5 Transaction Features: Rights Offering공시 • Feb 13Aqua Bio Technology ASA has filed a Follow-on Equity Offering in the amount of NOK 4 million.Aqua Bio Technology ASA has filed a Follow-on Equity Offering in the amount of NOK 4 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 800,000 Price\Range: NOK 5 Transaction Features: Rights OfferingNew Risk • Dec 22New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 46% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr18m free cash flow). Share price has been highly volatile over the past 3 months (30% average weekly change). Earnings have declined by 70% per year over the past 5 years. Shareholders have been substantially diluted in the past year (46% increase in shares outstanding). Market cap is less than US$10m (€6.56m market cap, or US$7.69m).New Risk • Dec 05New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 46% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr18m free cash flow). Share price has been highly volatile over the past 3 months (31% average weekly change). Earnings have declined by 70% per year over the past 5 years. Shareholders have been substantially diluted in the past year (46% increase in shares outstanding). Market cap is less than US$10m (€6.71m market cap, or US$7.81m).Reported Earnings • Dec 01Third quarter 2025 earnings releasedThird quarter 2025 results: Revenue: kr6.88m (down 70% from 3Q 2024). Net loss: kr5.13m (loss narrowed 97% from 3Q 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 18 percentage points per year, which is a significant difference in performance.New Risk • Nov 30New minor risk - Financial positionThe company has a high level of debt. Net debt to equity ratio: 1,462% This is considered a minor risk. Having a high level of debt increases the company's balance sheet risk. The company has a higher interest repayment burden, leading to the need to allocate a greater amount of its earnings towards servicing the debt, potentially limiting growth options or shareholder distributions. It can also increase the risk of bankruptcy if business conditions deteriorate enough that the company can no longer meet its debt obligations. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (30% average weekly change). High level of non-cash earnings (73% accrual ratio). Revenue is less than US$1m. Market cap is less than US$10m (€4.54m market cap, or US$5.27m). Minor Risk High level of debt (1,462% net debt to equity).공시 • Nov 22Aqua Bio Technology ASA, Annual General Meeting, May 22, 2026Aqua Bio Technology ASA, Annual General Meeting, May 22, 2026.공시 • Nov 21+ 3 more updatesAqua Bio Technology ASA to Report Q3, 2025 Results on Nov 26, 2025Aqua Bio Technology ASA announced that they will report Q3, 2025 results on Nov 26, 2025New Risk • Aug 31New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -kr32m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr32m free cash flow). Share price has been highly volatile over the past 3 months (27% average weekly change). Earnings have declined by 73% per year over the past 5 years. Shareholders have been substantially diluted in the past year (57% increase in shares outstanding). Market cap is less than US$10m (€7.30m market cap, or US$8.54m).공시 • May 22Coc Invest AS, Cover Consult AS, Fiala Holding As, Hartmanns Norge As, Kø Consulting AS and Odp Holding As entered into an agreement to acquire 3D Innovation Nordic AS from Aqua Bio Technology ASA (OB:ABTEC).Coc Invest AS, Cover Consult AS, Fiala Holding As, Hartmanns Norge As, Kø Consulting AS and Odp Holding As entered into an agreement to acquire 3D Innovation Nordic AS from Aqua Bio Technology ASA (OB:ABTEC) on May 20, 2025. In separate transactions Aqua Bio Technology ASA (ABTEC) has entered into agreements with Coc Invest AS, Odp Holding AS, Fiala Holding AS, Kø Consulting AS, Cover Consult AS, and Hartmanns Norge AS for the sale of Ovalen AS, Cover Brands As. The combined consideration for Ovalen AS, 3D Innovation Nordic AS, and Coverbrands AS will be settled in 11 million Aqua Bio Technology shares and NOK 0.5 million in cash.공시 • May 21Coc Invest AS, Odp Holding As, Fiala Holding As, Hartmanns Norge As, Kø Consulting AS and Cover Consult AS entered into an agreement to acquire Cover Brands As from Aqua Bio Technology ASA (OB:ABTEC).Coc Invest AS, Odp Holding As, Fiala Holding As, Hartmanns Norge As, Kø Consulting AS and Cover Consult AS entered into an agreement to acquire Cover Brands As from Aqua Bio Technology ASA (OB:ABTEC) on May 20, 2025. In separate transactions Aqua Bio Technology ASA (ABTEC) has entered into agreements with Coc Invest AS, Odp Holding AS, Fiala Holding AS, Kø Consulting AS, Cover Consult AS, and Hartmanns Norge AS for the sale of Ovalen AS, 3D Innovation Nordic AS. The combined consideration for Ovalen AS, 3D Innovation Nordic AS, and Coverbrands AS will be settled in 11 million Aqua Bio Technology shares and NOK 0.5 million in cash.공시 • Apr 09Aqua Bio Technology Asa Announces Board ChangesAqua Bio Technology ASA at the extraordinary general meeting held on 9 April 2025, Roger Sedal is elected as new Chairman of the Board of Directors. Jan Pettersson shall resign from the Board of Directors. Following this, the Board of Directors shall consist of: Roger Sedal, Chairman; Lena Aas Varming, Director; Sofie Aimee Siem, Director; David Huggins, Director; Terje Blytt, Director; Jon Olav Ødegård, Observer.공시 • Apr 04Aqua Bio Technology ASA has completed a Follow-on Equity Offering in the amount of NOK 2.055988 million.Aqua Bio Technology ASA has completed a Follow-on Equity Offering in the amount of NOK 2.055988 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 4,111,975 Price\Range: NOK 0.5 Transaction Features: Rights Offering공시 • Mar 13Aqua Bio Technology ASA has completed a Follow-on Equity Offering in the amount of NOK 24.216 million.Aqua Bio Technology ASA has completed a Follow-on Equity Offering in the amount of NOK 24.216 million. Security Name: Shares Security Type: Common Stock Securities Offered: 48,432,000 Price\Range: NOK 0.5 Transaction Features: Subsequent Direct ListingNew Risk • Mar 10New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: €6.87m (US$7.43m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (31% average weekly change). High level of non-cash earnings (41% accrual ratio). Shareholders have been substantially diluted in the past year (86% increase in shares outstanding). Market cap is less than US$10m (€6.87m market cap, or US$7.43m).공시 • Feb 26+ 2 more updatesAqua Bio Technology ASA, Annual General Meeting, Jun 25, 2025Aqua Bio Technology ASA, Annual General Meeting, Jun 25, 2025.공시 • Feb 12Aqua Bio Technology ASA Provides Earnings Guidance for the Fiscal Year 2025Aqua Bio Technology ASA provided earnings guidance for the fiscal year 2025. For the period, consolidated revenue is expected to exceed NOK 500.0 million applying Norwegian Generally Accepted Accounting Principles (N-GAAP), indicating conservative revenue growth compared to pro forma revenue (based on N-GAAP) assuming all 2024 acquisitions were completed as of January 1, 2024.공시 • Jan 21Aqua Bio Technology Announces Resignation of Celine Maria Sedal from Board of DirectorsAqua Bio Technology ASA has been informed that Board member Celine Maria Sedal has chosen to resign from the Company's Board of Directors with immediate effect. The resignation is due to Sedal not being able to hold the position as member of the Board of Directors in her newly assumed employment.New Risk • Dec 30New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (21% average weekly change). High level of non-cash earnings (41% accrual ratio). Shareholders have been substantially diluted in the past year (97% increase in shares outstanding). Minor Risk Market cap is less than US$100m (€19.8m market cap, or US$20.6m).New Risk • Nov 22New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 130% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Shareholders have been substantially diluted in the past year (130% increase in shares outstanding). Minor Risks Revenue is less than US$5m (kr14m revenue, or US$1.2m). Market cap is less than US$100m (€17.6m market cap, or US$18.3m).New Risk • Nov 13New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (11% average weekly change). Minor Risks Shareholders have been diluted in the past year (47% increase in shares outstanding). Revenue is less than US$5m (kr14m revenue, or US$1.2m). Market cap is less than US$100m (€16.2m market cap, or US$17.3m).공시 • Oct 22Aqua Bio Technology ASA Announces CEO Changes, Effective December 1, 2024Aqua Bio Technology ASA announced that Fredrik W. Henriksen has been appointed Chief Executive Officer of the Company. Mr. Henriksen assumes his position on 1 December 2024, and replaces Håvard Lindstrøm, who has served as CEO for more than 3 years. Mr. Henriksen has since 2016 served as Commercial Director in Norengros. He has also 15 years in different start-ups prior to working within the sales and distribution industry. Håvard Lindstrøm started as CEO in 2021.공시 • Aug 29Aqua Bio Technology ASA (OB:ABTEC) completed the acquisition of 3d Innovation Nordic As from Coc Invest AS.Aqua Bio Technology ASA (OB:ABTEC) entered into an agreement to acquire 3d Innovation Nordic As from Coc Invest AS on April 25, 2024. Pursuant to the Agreement, Aqua Bio Technology also agreed to acquire Printprofil AS and Check Please AS from Coc Invest AS. The combined consideration for both the transactions is NOK 40.4 million. Under the Agreement, the purchase price for the Acquisitions shall be settled in a combination of shares and cash, subject to certain conditions. NOK 5 million shares in ABT will be issued at a price of NOK 6 per share, with a 3-year lock up. The cash will be total NOK 15 million, divided into two installments, depending on the Target Group's (collectively Printprofil AS and Check Please AS (jointly with 3D Innovation) financial results. The first NOK 5 million is triggered by an EBT of NOK 6 million in the Target Group, the next NOK 10 million when the Target Group achieves an EBT of NOK 10 million. As of 2023, 3d Innovation, Printprofil AS and Check Please had reported a EBIDTA of NOK 5 million and turnover of NOK 87.6 million, of which 3d Innovation had a turnover of NOK 73 million. The completion of the Acquisitions is subject to satisfactory due diligence and approval from ABT's board of directors. Aqua Bio Technology ASA (OB:ABTEC) completed the acquisition of 3d Innovation Nordic As from Coc Invest AS on August 28, 2024. The purchase price for the Transaction shall be settled in a combination of shares and cash, subject to certain conditions. The share component comprises of ABT issuing 5 million new shares at subscription price of NOK 3.66 per share, equal to today's opening trading price of the Company's shares, with a 3-year lock up (the "Consideration Shares"). The cash component will in total be NOK 15 million, divided into two installments, depending on the Target Group's financial results. The first NOK 5 million is triggered by an EBT of NOK 6 million in the Target Group, the next NOK 10 million when the Target Group achieves an EBT of NOK 10 million. The Company's board of directors will convene at a later date to formally issue the Consideration Shares. The Transaction has been completed making ABT the 100 % direct and indirect owner of the Printprofil AS and Check Please AS (jointly with 3D, the "Target Group").New Risk • Aug 24New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended June 2023. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported June 2023 fiscal period end). Share price has been highly volatile over the past 3 months (12% average weekly change). Shareholders have been substantially diluted in the past year (209% increase in shares outstanding). Minor Risks Revenue is less than US$5m (kr14m revenue, or US$1.3m). Market cap is less than US$100m (€20.9m market cap, or US$23.4m).New Risk • Jun 12New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Shareholders have been substantially diluted in the past year (181% increase in shares outstanding). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Revenue is less than US$5m (kr14m revenue, or US$1.3m). Market cap is less than US$100m (€19.9m market cap, or US$21.5m).공시 • Apr 28+ 3 more updatesAqua Bio Technology ASA to Report Q4, 2024 Results on Feb 12, 2025Aqua Bio Technology ASA announced that they will report Q4, 2024 results on Feb 12, 2025New Risk • Mar 11New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (36% average weekly change). Shareholders have been substantially diluted in the past year (183% increase in shares outstanding). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Revenue is less than US$5m (kr14m revenue, or US$1.3m). Market cap is less than US$100m (€21.6m market cap, or US$23.7m).공시 • Feb 01Aqua Bio Technology ASA has filed a Follow-on Equity Offering in the amount of NOK 5 million.Aqua Bio Technology ASA has filed a Follow-on Equity Offering in the amount of NOK 5 million. Security Name: Shares Security Type: Common Stock Securities Offered: 1,000,000 Price\Range: NOK 5 Transaction Features: Rights Offering공시 • Jan 30+ 1 more updateAqua Bio Technology ASA has filed a Follow-on Equity Offering in the amount of NOK 15 million.Aqua Bio Technology ASA has filed a Follow-on Equity Offering in the amount of NOK 15 million. Security Name: Shares Security Type: Common Stock Securities Offered: 3,000,000 Price\Range: NOK 5 Transaction Features: Subsequent Direct Listing공시 • Dec 21Aqua Bio Technology ASA (OB:ABTEC) entered into a share purchase agreement to acquire Cover Brands As from Medvind Holding As for NOK 16.5 million.Aqua Bio Technology ASA (OB:ABTEC) entered into a share purchase agreement to acquire Cover Brands As from Medvind Holding As for NOK 15.12 million on 19 December 2023. The purchase price will be settled through the Company issuing 6 million shares. Coverbrands revenue was above NOK 100 million.New Risk • Sep 15New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 129% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (21% average weekly change). Shareholders have been substantially diluted in the past year (129% increase in shares outstanding). Minor Risks Revenue is less than US$5m (kr14m revenue, or US$1.3m). Market cap is less than US$100m (€17.2m market cap, or US$18.3m).공시 • Sep 13Aqua Bio Technology Asa Receives European Patent for Use of Chaga in Cosmetic FormulationsAqua Bio Technology ASA (ABT) has been granted a European patent for use of Chaga in cosmetic formulations until 2037. This latest patent secures the rights in both US and Europe. The Chaga mushroom grows on birch trees throughout the northern hemisphere. The extract from Chagas mushroom has shown good results on wrinkles and general skin improvement. The extraction from Chagas mushroom can be beneficial for anyone suffering from skin conditions such as acne, allergic reactions, rashes, dermatitis, psoriasis, rosacea and eczema. The European and US patent secures ABT's use of this ingredient in existing and future cosmetic products and prohibits other players to use this ingredient without a specific license from ABT.New Risk • Aug 23New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 9.1% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (20% average weekly change). Revenue is less than US$1m (kr7.2m revenue, or US$675k). Market cap is less than US$10m (€7.40m market cap, or US$8.03m). Minor Risk Shareholders have been diluted in the past year (9.1% increase in shares outstanding).공시 • Jul 26Aqua Bio Technology ASA announced that it has received NOK 75.999999 million in fundingOn July 24, 2023, Aqua Bio Technology ASA closed the transaction. The company issued 25,333,333 common shares at an issue price of NOK 3 per share for gross proceeds of NOK 76,000,000. The transaction included participation from shareholders of Skinteam Norge AS and certain investors of the company.공시 • Jul 25Aqua Bio Technology ASA announced that it expects to receive NOK 76 million in fundingAqua Bio Technology ASA announced a private placement for gross proceeds of NOK 76 million on July 24, 2023.공시 • Jul 24Aqua Bio Technology ASA (OB:ABTEC) entered into a binding agreement in principle to acquire SkinTeam Norge AS for NOK 45 million.Aqua Bio Technology ASA (OB:ABTEC) entered into a binding agreement in principle to acquire SkinTeam Norge AS for NOK 45 million on July 23, 2023. The purchase price will be used to subscribe for new shares in Aqua Bio Technology at a subscription price of NOK 3.공시 • Jan 21Aqua Bio Technology ASA Provides Earnings Guidance for the Full Year 2023Aqua Bio Technology ASA provided earnings guidance for the full year 2023. For the period, the company estimated gross income in 2023 for the company is approximately NOK 20-22 million with a gross margin of approximately between 65-70%.공시 • Dec 14+ 2 more updatesAqua Bio Technology ASA, Annual General Meeting, Apr 28, 2023Aqua Bio Technology ASA, Annual General Meeting, Apr 28, 2023.Board Change • Nov 16No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 1 highly experienced director. No independent directors (5 non-independent directors). Director Roger Hofseth was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.공시 • Jul 29Aqua Bio Technology ASA (OB:ABT) acquired Cosmed Beauty AS and Ultrabody AB from Varming Holding As.Aqua Bio Technology ASA (OB:ABT) entered into a binding term sheet to acquire Cosmed Beauty AS and Ultrabody AB from Varming Holding As on June 28, 2022. The purchase price will be based on a earn-out based on a multiple of Cosmed's result before tax for each of the financial year 2022, 2023, 2024 and 2025. The majority of the purchase price (appr. 3/4) will be used to subscribe for new shares in ABT at a subscription price of NOK 8,20 following Cosmed's adoption of its annual accounts for 2022-2025. The transaction will be completed following a satisfactory due diligence and ABT's board approval. The Parties shall finalize a share purchase agreement within 31 July 2022. Aqua Bio Technology ASA (OB:ABT) completed the acquisition of Cosmed Beauty AS and Ultrabody AB from Varming Holding As on June 28, 2022.공시 • Jun 30Aqua Bio Technology ASA (OB:ABT) entered into a binding term sheet to acquire Cosmed Beauty AS and Ultrabody AB from Varming Holding As.Aqua Bio Technology ASA (OB:ABT) entered into a binding term sheet to acquire Cosmed Beauty AS and Ultrabody AB from Varming Holding As on June 28, 2022. The purchase price will be based on a earn-out based on a multiple of Cosmed's result before tax for each of the financial year 2022, 2023, 2024 and 2025. The majority of the purchase price (appr. 3/4) will be used to subscribe for new shares in ABT at a subscription price of NOK 8,20 following Cosmed's adoption of its annual accounts for 2022-2025. The transaction will be completed following a satisfactory due diligence and ABT's board approval. The Parties shall finalize a share purchase agreement within 31 July 2022.Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 1 highly experienced director. No independent directors (5 non-independent directors). Director Roger Hofseth was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.공시 • Apr 12Aqua Bio Technology ASA Announces Hydrafacial Launches Products Containing Aquabeautine XL in the UKAqua Bio Technology ASA announced that Hydrafacial has now launched Restorsea Lip Fix Kit which is based on ABT's hatching fluid ingredient (Aquabeautine XL) in the UK. The kit includes the RestorseaTM Lip Serum, to be administered during the lip treatment, and the Lip Elixir gloss as a hydrator and natural exfoliator to be applied post-treatment. Restorsea has built its company and business idea on Aquabeautine XL and has through 2021 had increasing orders of Aquabeautine XL which fit in-line with its expanded distribution. Restorsea is distributing products, own and out-licensed and all basen on ABT's hatching fluid Ingredient Aquabeautine XL, in South Korea, US, Brazil, and in approx 130 doctors offices in the US (Restorsea-branded products) as well as distribution through Nasdaq-listed Hydrafacial in the US and UK (Restorsea-developed products for Hydrafacial Perk) and in the US through Nasdaq-listed LifeMD (private label).Board Change • Sep 30No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Director Roger Hofseth was the last director to join the board, commencing their role in 2019. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 3FZ0 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: 3FZ0 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장Aqua Bio Technology 배당 수익률 vs 시장3FZ0의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (3FZ0)0%시장 하위 25% (DE)1.5%시장 상위 25% (DE)4.5%업계 평균 (Chemicals)3.8%분석가 예측 (3FZ0) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 3FZ0 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 3FZ0 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 3FZ0 German 시장에서 주목할만한 배당금을 지급하지 않습니다.주주 현금 배당현금 흐름 범위: 3FZ0 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YDE 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/20 16:27종가2026/05/20 00:00수익2025/12/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Aqua Bio Technology ASA는 1명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Tomas SkeivysNorne Securities AS
New Risk • May 13New major risk - Revenue sizeThe company makes less than US$1m in revenue. Total revenue: kr7.5m (US$822k) This is considered a major risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (633% average daily change). Earnings have declined by 62% per year over the past 5 years. Shareholders have been substantially diluted in the past year (over 6x increase in shares outstanding). Revenue is less than US$1m (kr7.5m revenue, or US$822k). Market cap is less than US$10m (€7.17m market cap, or US$8.40m).
공시 • Mar 21Aqua Bio Technology ASA has completed a Follow-on Equity Offering in the amount of NOK 3.6824 million.Aqua Bio Technology ASA has completed a Follow-on Equity Offering in the amount of NOK 3.6824 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 388,240 Price\Range: NOK 5 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 348,240 Price\Range: NOK 5 Transaction Features: Rights Offering
공시 • Feb 13Aqua Bio Technology ASA has filed a Follow-on Equity Offering in the amount of NOK 4 million.Aqua Bio Technology ASA has filed a Follow-on Equity Offering in the amount of NOK 4 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 800,000 Price\Range: NOK 5 Transaction Features: Rights Offering
New Risk • Dec 22New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 46% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr18m free cash flow). Share price has been highly volatile over the past 3 months (30% average weekly change). Earnings have declined by 70% per year over the past 5 years. Shareholders have been substantially diluted in the past year (46% increase in shares outstanding). Market cap is less than US$10m (€6.56m market cap, or US$7.69m).
New Risk • Dec 05New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 46% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr18m free cash flow). Share price has been highly volatile over the past 3 months (31% average weekly change). Earnings have declined by 70% per year over the past 5 years. Shareholders have been substantially diluted in the past year (46% increase in shares outstanding). Market cap is less than US$10m (€6.71m market cap, or US$7.81m).
Reported Earnings • Dec 01Third quarter 2025 earnings releasedThird quarter 2025 results: Revenue: kr6.88m (down 70% from 3Q 2024). Net loss: kr5.13m (loss narrowed 97% from 3Q 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 18 percentage points per year, which is a significant difference in performance.
New Risk • Nov 30New minor risk - Financial positionThe company has a high level of debt. Net debt to equity ratio: 1,462% This is considered a minor risk. Having a high level of debt increases the company's balance sheet risk. The company has a higher interest repayment burden, leading to the need to allocate a greater amount of its earnings towards servicing the debt, potentially limiting growth options or shareholder distributions. It can also increase the risk of bankruptcy if business conditions deteriorate enough that the company can no longer meet its debt obligations. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (30% average weekly change). High level of non-cash earnings (73% accrual ratio). Revenue is less than US$1m. Market cap is less than US$10m (€4.54m market cap, or US$5.27m). Minor Risk High level of debt (1,462% net debt to equity).
공시 • Nov 22Aqua Bio Technology ASA, Annual General Meeting, May 22, 2026Aqua Bio Technology ASA, Annual General Meeting, May 22, 2026.
공시 • Nov 21+ 3 more updatesAqua Bio Technology ASA to Report Q3, 2025 Results on Nov 26, 2025Aqua Bio Technology ASA announced that they will report Q3, 2025 results on Nov 26, 2025
New Risk • Aug 31New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -kr32m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr32m free cash flow). Share price has been highly volatile over the past 3 months (27% average weekly change). Earnings have declined by 73% per year over the past 5 years. Shareholders have been substantially diluted in the past year (57% increase in shares outstanding). Market cap is less than US$10m (€7.30m market cap, or US$8.54m).
공시 • May 22Coc Invest AS, Cover Consult AS, Fiala Holding As, Hartmanns Norge As, Kø Consulting AS and Odp Holding As entered into an agreement to acquire 3D Innovation Nordic AS from Aqua Bio Technology ASA (OB:ABTEC).Coc Invest AS, Cover Consult AS, Fiala Holding As, Hartmanns Norge As, Kø Consulting AS and Odp Holding As entered into an agreement to acquire 3D Innovation Nordic AS from Aqua Bio Technology ASA (OB:ABTEC) on May 20, 2025. In separate transactions Aqua Bio Technology ASA (ABTEC) has entered into agreements with Coc Invest AS, Odp Holding AS, Fiala Holding AS, Kø Consulting AS, Cover Consult AS, and Hartmanns Norge AS for the sale of Ovalen AS, Cover Brands As. The combined consideration for Ovalen AS, 3D Innovation Nordic AS, and Coverbrands AS will be settled in 11 million Aqua Bio Technology shares and NOK 0.5 million in cash.
공시 • May 21Coc Invest AS, Odp Holding As, Fiala Holding As, Hartmanns Norge As, Kø Consulting AS and Cover Consult AS entered into an agreement to acquire Cover Brands As from Aqua Bio Technology ASA (OB:ABTEC).Coc Invest AS, Odp Holding As, Fiala Holding As, Hartmanns Norge As, Kø Consulting AS and Cover Consult AS entered into an agreement to acquire Cover Brands As from Aqua Bio Technology ASA (OB:ABTEC) on May 20, 2025. In separate transactions Aqua Bio Technology ASA (ABTEC) has entered into agreements with Coc Invest AS, Odp Holding AS, Fiala Holding AS, Kø Consulting AS, Cover Consult AS, and Hartmanns Norge AS for the sale of Ovalen AS, 3D Innovation Nordic AS. The combined consideration for Ovalen AS, 3D Innovation Nordic AS, and Coverbrands AS will be settled in 11 million Aqua Bio Technology shares and NOK 0.5 million in cash.
공시 • Apr 09Aqua Bio Technology Asa Announces Board ChangesAqua Bio Technology ASA at the extraordinary general meeting held on 9 April 2025, Roger Sedal is elected as new Chairman of the Board of Directors. Jan Pettersson shall resign from the Board of Directors. Following this, the Board of Directors shall consist of: Roger Sedal, Chairman; Lena Aas Varming, Director; Sofie Aimee Siem, Director; David Huggins, Director; Terje Blytt, Director; Jon Olav Ødegård, Observer.
공시 • Apr 04Aqua Bio Technology ASA has completed a Follow-on Equity Offering in the amount of NOK 2.055988 million.Aqua Bio Technology ASA has completed a Follow-on Equity Offering in the amount of NOK 2.055988 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 4,111,975 Price\Range: NOK 0.5 Transaction Features: Rights Offering
공시 • Mar 13Aqua Bio Technology ASA has completed a Follow-on Equity Offering in the amount of NOK 24.216 million.Aqua Bio Technology ASA has completed a Follow-on Equity Offering in the amount of NOK 24.216 million. Security Name: Shares Security Type: Common Stock Securities Offered: 48,432,000 Price\Range: NOK 0.5 Transaction Features: Subsequent Direct Listing
New Risk • Mar 10New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: €6.87m (US$7.43m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (31% average weekly change). High level of non-cash earnings (41% accrual ratio). Shareholders have been substantially diluted in the past year (86% increase in shares outstanding). Market cap is less than US$10m (€6.87m market cap, or US$7.43m).
공시 • Feb 26+ 2 more updatesAqua Bio Technology ASA, Annual General Meeting, Jun 25, 2025Aqua Bio Technology ASA, Annual General Meeting, Jun 25, 2025.
공시 • Feb 12Aqua Bio Technology ASA Provides Earnings Guidance for the Fiscal Year 2025Aqua Bio Technology ASA provided earnings guidance for the fiscal year 2025. For the period, consolidated revenue is expected to exceed NOK 500.0 million applying Norwegian Generally Accepted Accounting Principles (N-GAAP), indicating conservative revenue growth compared to pro forma revenue (based on N-GAAP) assuming all 2024 acquisitions were completed as of January 1, 2024.
공시 • Jan 21Aqua Bio Technology Announces Resignation of Celine Maria Sedal from Board of DirectorsAqua Bio Technology ASA has been informed that Board member Celine Maria Sedal has chosen to resign from the Company's Board of Directors with immediate effect. The resignation is due to Sedal not being able to hold the position as member of the Board of Directors in her newly assumed employment.
New Risk • Dec 30New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (21% average weekly change). High level of non-cash earnings (41% accrual ratio). Shareholders have been substantially diluted in the past year (97% increase in shares outstanding). Minor Risk Market cap is less than US$100m (€19.8m market cap, or US$20.6m).
New Risk • Nov 22New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 130% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Shareholders have been substantially diluted in the past year (130% increase in shares outstanding). Minor Risks Revenue is less than US$5m (kr14m revenue, or US$1.2m). Market cap is less than US$100m (€17.6m market cap, or US$18.3m).
New Risk • Nov 13New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (11% average weekly change). Minor Risks Shareholders have been diluted in the past year (47% increase in shares outstanding). Revenue is less than US$5m (kr14m revenue, or US$1.2m). Market cap is less than US$100m (€16.2m market cap, or US$17.3m).
공시 • Oct 22Aqua Bio Technology ASA Announces CEO Changes, Effective December 1, 2024Aqua Bio Technology ASA announced that Fredrik W. Henriksen has been appointed Chief Executive Officer of the Company. Mr. Henriksen assumes his position on 1 December 2024, and replaces Håvard Lindstrøm, who has served as CEO for more than 3 years. Mr. Henriksen has since 2016 served as Commercial Director in Norengros. He has also 15 years in different start-ups prior to working within the sales and distribution industry. Håvard Lindstrøm started as CEO in 2021.
공시 • Aug 29Aqua Bio Technology ASA (OB:ABTEC) completed the acquisition of 3d Innovation Nordic As from Coc Invest AS.Aqua Bio Technology ASA (OB:ABTEC) entered into an agreement to acquire 3d Innovation Nordic As from Coc Invest AS on April 25, 2024. Pursuant to the Agreement, Aqua Bio Technology also agreed to acquire Printprofil AS and Check Please AS from Coc Invest AS. The combined consideration for both the transactions is NOK 40.4 million. Under the Agreement, the purchase price for the Acquisitions shall be settled in a combination of shares and cash, subject to certain conditions. NOK 5 million shares in ABT will be issued at a price of NOK 6 per share, with a 3-year lock up. The cash will be total NOK 15 million, divided into two installments, depending on the Target Group's (collectively Printprofil AS and Check Please AS (jointly with 3D Innovation) financial results. The first NOK 5 million is triggered by an EBT of NOK 6 million in the Target Group, the next NOK 10 million when the Target Group achieves an EBT of NOK 10 million. As of 2023, 3d Innovation, Printprofil AS and Check Please had reported a EBIDTA of NOK 5 million and turnover of NOK 87.6 million, of which 3d Innovation had a turnover of NOK 73 million. The completion of the Acquisitions is subject to satisfactory due diligence and approval from ABT's board of directors. Aqua Bio Technology ASA (OB:ABTEC) completed the acquisition of 3d Innovation Nordic As from Coc Invest AS on August 28, 2024. The purchase price for the Transaction shall be settled in a combination of shares and cash, subject to certain conditions. The share component comprises of ABT issuing 5 million new shares at subscription price of NOK 3.66 per share, equal to today's opening trading price of the Company's shares, with a 3-year lock up (the "Consideration Shares"). The cash component will in total be NOK 15 million, divided into two installments, depending on the Target Group's financial results. The first NOK 5 million is triggered by an EBT of NOK 6 million in the Target Group, the next NOK 10 million when the Target Group achieves an EBT of NOK 10 million. The Company's board of directors will convene at a later date to formally issue the Consideration Shares. The Transaction has been completed making ABT the 100 % direct and indirect owner of the Printprofil AS and Check Please AS (jointly with 3D, the "Target Group").
New Risk • Aug 24New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended June 2023. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported June 2023 fiscal period end). Share price has been highly volatile over the past 3 months (12% average weekly change). Shareholders have been substantially diluted in the past year (209% increase in shares outstanding). Minor Risks Revenue is less than US$5m (kr14m revenue, or US$1.3m). Market cap is less than US$100m (€20.9m market cap, or US$23.4m).
New Risk • Jun 12New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Shareholders have been substantially diluted in the past year (181% increase in shares outstanding). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Revenue is less than US$5m (kr14m revenue, or US$1.3m). Market cap is less than US$100m (€19.9m market cap, or US$21.5m).
공시 • Apr 28+ 3 more updatesAqua Bio Technology ASA to Report Q4, 2024 Results on Feb 12, 2025Aqua Bio Technology ASA announced that they will report Q4, 2024 results on Feb 12, 2025
New Risk • Mar 11New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (36% average weekly change). Shareholders have been substantially diluted in the past year (183% increase in shares outstanding). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Revenue is less than US$5m (kr14m revenue, or US$1.3m). Market cap is less than US$100m (€21.6m market cap, or US$23.7m).
공시 • Feb 01Aqua Bio Technology ASA has filed a Follow-on Equity Offering in the amount of NOK 5 million.Aqua Bio Technology ASA has filed a Follow-on Equity Offering in the amount of NOK 5 million. Security Name: Shares Security Type: Common Stock Securities Offered: 1,000,000 Price\Range: NOK 5 Transaction Features: Rights Offering
공시 • Jan 30+ 1 more updateAqua Bio Technology ASA has filed a Follow-on Equity Offering in the amount of NOK 15 million.Aqua Bio Technology ASA has filed a Follow-on Equity Offering in the amount of NOK 15 million. Security Name: Shares Security Type: Common Stock Securities Offered: 3,000,000 Price\Range: NOK 5 Transaction Features: Subsequent Direct Listing
공시 • Dec 21Aqua Bio Technology ASA (OB:ABTEC) entered into a share purchase agreement to acquire Cover Brands As from Medvind Holding As for NOK 16.5 million.Aqua Bio Technology ASA (OB:ABTEC) entered into a share purchase agreement to acquire Cover Brands As from Medvind Holding As for NOK 15.12 million on 19 December 2023. The purchase price will be settled through the Company issuing 6 million shares. Coverbrands revenue was above NOK 100 million.
New Risk • Sep 15New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 129% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (21% average weekly change). Shareholders have been substantially diluted in the past year (129% increase in shares outstanding). Minor Risks Revenue is less than US$5m (kr14m revenue, or US$1.3m). Market cap is less than US$100m (€17.2m market cap, or US$18.3m).
공시 • Sep 13Aqua Bio Technology Asa Receives European Patent for Use of Chaga in Cosmetic FormulationsAqua Bio Technology ASA (ABT) has been granted a European patent for use of Chaga in cosmetic formulations until 2037. This latest patent secures the rights in both US and Europe. The Chaga mushroom grows on birch trees throughout the northern hemisphere. The extract from Chagas mushroom has shown good results on wrinkles and general skin improvement. The extraction from Chagas mushroom can be beneficial for anyone suffering from skin conditions such as acne, allergic reactions, rashes, dermatitis, psoriasis, rosacea and eczema. The European and US patent secures ABT's use of this ingredient in existing and future cosmetic products and prohibits other players to use this ingredient without a specific license from ABT.
New Risk • Aug 23New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 9.1% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (20% average weekly change). Revenue is less than US$1m (kr7.2m revenue, or US$675k). Market cap is less than US$10m (€7.40m market cap, or US$8.03m). Minor Risk Shareholders have been diluted in the past year (9.1% increase in shares outstanding).
공시 • Jul 26Aqua Bio Technology ASA announced that it has received NOK 75.999999 million in fundingOn July 24, 2023, Aqua Bio Technology ASA closed the transaction. The company issued 25,333,333 common shares at an issue price of NOK 3 per share for gross proceeds of NOK 76,000,000. The transaction included participation from shareholders of Skinteam Norge AS and certain investors of the company.
공시 • Jul 25Aqua Bio Technology ASA announced that it expects to receive NOK 76 million in fundingAqua Bio Technology ASA announced a private placement for gross proceeds of NOK 76 million on July 24, 2023.
공시 • Jul 24Aqua Bio Technology ASA (OB:ABTEC) entered into a binding agreement in principle to acquire SkinTeam Norge AS for NOK 45 million.Aqua Bio Technology ASA (OB:ABTEC) entered into a binding agreement in principle to acquire SkinTeam Norge AS for NOK 45 million on July 23, 2023. The purchase price will be used to subscribe for new shares in Aqua Bio Technology at a subscription price of NOK 3.
공시 • Jan 21Aqua Bio Technology ASA Provides Earnings Guidance for the Full Year 2023Aqua Bio Technology ASA provided earnings guidance for the full year 2023. For the period, the company estimated gross income in 2023 for the company is approximately NOK 20-22 million with a gross margin of approximately between 65-70%.
공시 • Dec 14+ 2 more updatesAqua Bio Technology ASA, Annual General Meeting, Apr 28, 2023Aqua Bio Technology ASA, Annual General Meeting, Apr 28, 2023.
Board Change • Nov 16No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 1 highly experienced director. No independent directors (5 non-independent directors). Director Roger Hofseth was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
공시 • Jul 29Aqua Bio Technology ASA (OB:ABT) acquired Cosmed Beauty AS and Ultrabody AB from Varming Holding As.Aqua Bio Technology ASA (OB:ABT) entered into a binding term sheet to acquire Cosmed Beauty AS and Ultrabody AB from Varming Holding As on June 28, 2022. The purchase price will be based on a earn-out based on a multiple of Cosmed's result before tax for each of the financial year 2022, 2023, 2024 and 2025. The majority of the purchase price (appr. 3/4) will be used to subscribe for new shares in ABT at a subscription price of NOK 8,20 following Cosmed's adoption of its annual accounts for 2022-2025. The transaction will be completed following a satisfactory due diligence and ABT's board approval. The Parties shall finalize a share purchase agreement within 31 July 2022. Aqua Bio Technology ASA (OB:ABT) completed the acquisition of Cosmed Beauty AS and Ultrabody AB from Varming Holding As on June 28, 2022.
공시 • Jun 30Aqua Bio Technology ASA (OB:ABT) entered into a binding term sheet to acquire Cosmed Beauty AS and Ultrabody AB from Varming Holding As.Aqua Bio Technology ASA (OB:ABT) entered into a binding term sheet to acquire Cosmed Beauty AS and Ultrabody AB from Varming Holding As on June 28, 2022. The purchase price will be based on a earn-out based on a multiple of Cosmed's result before tax for each of the financial year 2022, 2023, 2024 and 2025. The majority of the purchase price (appr. 3/4) will be used to subscribe for new shares in ABT at a subscription price of NOK 8,20 following Cosmed's adoption of its annual accounts for 2022-2025. The transaction will be completed following a satisfactory due diligence and ABT's board approval. The Parties shall finalize a share purchase agreement within 31 July 2022.
Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 1 highly experienced director. No independent directors (5 non-independent directors). Director Roger Hofseth was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
공시 • Apr 12Aqua Bio Technology ASA Announces Hydrafacial Launches Products Containing Aquabeautine XL in the UKAqua Bio Technology ASA announced that Hydrafacial has now launched Restorsea Lip Fix Kit which is based on ABT's hatching fluid ingredient (Aquabeautine XL) in the UK. The kit includes the RestorseaTM Lip Serum, to be administered during the lip treatment, and the Lip Elixir gloss as a hydrator and natural exfoliator to be applied post-treatment. Restorsea has built its company and business idea on Aquabeautine XL and has through 2021 had increasing orders of Aquabeautine XL which fit in-line with its expanded distribution. Restorsea is distributing products, own and out-licensed and all basen on ABT's hatching fluid Ingredient Aquabeautine XL, in South Korea, US, Brazil, and in approx 130 doctors offices in the US (Restorsea-branded products) as well as distribution through Nasdaq-listed Hydrafacial in the US and UK (Restorsea-developed products for Hydrafacial Perk) and in the US through Nasdaq-listed LifeMD (private label).
Board Change • Sep 30No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Director Roger Hofseth was the last director to join the board, commencing their role in 2019. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.